Vanda Pharmaceuticals
VNDA
188 hedge funds and large institutions have $604M invested in Vanda Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 22 funds opening new positions, 62 increasing their positions, 74 reducing their positions, and 31 closing their positions.
39% more call options, than puts
Call options by funds: $1.02M | Put options by funds: $735K
3.26% more ownership
Funds ownership: 97.41% → 100.68% (+3.3%)
5% less funds holding
Funds holding: 198 → 188 (-10)
16% less repeat investments, than reductions
Existing positions increased: 62 | Existing positions reduced: 74
29% less capital invested
Capital invested by funds: $851M → $604M (-$247M)
29% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$11.5M |
| 2 |
State Street
Boston,
Massachusetts
|
+$9.67M |
| 3 |
EIP
Epoch Investment Partners
New York
|
+$8.12M |
| 4 |
Millennium Management
New York
|
+$5.18M |
| 5 |
Hotchkis & Wiley Capital Management
Los Angeles,
California
|
+$4.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$7.84M |
| 2 |
PAI
Palo Alto Investors
Palo Alto,
California
|
-$4.51M |
| 3 |
Northern Trust
Chicago,
Illinois
|
-$2.57M |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$2.52M |
| 5 |
Bank of New York Mellon
New York
|
-$2.51M |
VNDA Hedge Fund Activity: Q1 2022 in Review
188 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Vanda Pharmaceuticals (VNDA) for Q1 2022, worth a combined $604M — down 29% from $851M a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of VNDA and 22 opened new positions — a net loss of 9 holders — while 74 trimmed existing stakes and 62 added.
The largest buyer was Assenagon Asset Management, adding an estimated $11.5M. The largest seller was Deep Track Capital, exiting entirely with an estimated $7.84M sold.
- 188 institutional investors held Vanda Pharmaceuticals (VNDA) as of Q1 2022, down from 198 in Q4 2021.
- Funds reported $604M of Vanda Pharmaceuticals stock for Q1 2022, down 29% quarter-over-quarter.
- 22 funds opened new Vanda Pharmaceuticals positions in Q1 2022 and 31 closed out, a net change of -9 holders.
- The largest Vanda Pharmaceuticals buyer in Q1 2022 was Assenagon Asset Management, an estimated $11.5M added.
- The largest Vanda Pharmaceuticals seller in Q1 2022 was Deep Track Capital, an estimated $7.84M sold.
Based on aggregated 13F filings for Q1 2022.